Natsar Pharmaceuticals, Inc. — SEC Form D Filing

Natsar Pharmaceuticals, Inc. filed an SEC Form D on May 8, 2026, reporting $4.22M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
May 8, 2026
Amount reported
$4.22M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://www.natsarpharmaceuticals.com/

What the company does

Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

DDX3 is overexpressed in many cancer types and is associated with lower survival rates in patients with diseases such as lung cancer.

Solution

Natsar Pharmaceuticals is developing a DDX3 inhibitor, RK-33, designed to impede DDX3 function, thereby inducing apoptosis and promoting radiation sensitization in cancer cells to treat conditions like lung, brain, and breast cancer, among others.

Verdict

Investors approved Natsar Pharmaceuticals' narrative primarily due to the urgency surrounding cancer treatment advancements, a clear focus on DDX3's role in survival rates, and the potential of RK-33 as a targeted therapy. This cleared because the technology targets a critical biological mechanism, not because the company presented a fully fleshed-out commercial strategy. However, the limited upside lies in the high failure rate typical of drug development and the uncertain market access given competitive oncology treatments.

Source: SEC EDGAR Form D filing